Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q86SJ6
UPID:
DSG4_HUMAN
Alternative names:
Cadherin family member 13
Alternative UPACC:
Q86SJ6; A2RUI1; Q6Y9L9; Q8IXV4
Background:
Desmoglein-4, also known as Cadherin family member 13, plays a crucial role in the formation of intercellular desmosome junctions. It is pivotal in facilitating cell-cell adhesion and orchestrating the transition from proliferation to differentiation in hair follicle keratinocytes. This protein's function underscores its importance in maintaining the structural integrity and function of the skin and hair follicles.
Therapeutic significance:
Desmoglein-4's involvement in Hypotrichosis 6, a condition marked by reduced hair quantity and abnormal hair follicles, highlights its potential as a therapeutic target. Understanding the role of Desmoglein-4 could open doors to potential therapeutic strategies for treating hair growth disorders and improving skin health.